Lumykras

Lumykras (Sotorasib) is an oral medication used to treat certain types of cancer. This pharmaceutical is manufactured by Amgen Europe B.V. and is designed for oral use.

Lumykras is primarily used in the treatment of specific cancers. It targets mutations in the KRAS gene, which are found in some types of cancer. Patients often wonder, 'What is Lumykras used for?' This medication is typically prescribed for advanced or metastatic non-small cell lung cancer with a specific KRAS G12C mutation.

Common effects of Lumykras may include fatigue, nausea, and diarrhea. Some patients may also experience muscle pain or changes in taste. These effects can vary from person to person and are not experienced by everyone who takes the medication.

Lumykras should be handled with care and stored as directed. It is important to follow the advice of a healthcare professional regarding its use. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions.

Lumykras may interact with certain medications, including those that are metabolized by the liver. It is important to discuss all current medications with a healthcare provider before starting Lumykras. Alcohol and other substances may also affect how Lumykras works in the body.